Comparative Pharmacology
Head-to-head clinical analysis: MYCIFRADIN versus NEO FRADIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCIFRADIN versus NEO FRADIN.
MYCIFRADIN vs NEO-FRADIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis by causing misreading of mRNA and incorporation of incorrect amino acids into the growing peptide chain.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis. It also disrupts bacterial cell membrane integrity.
1-2 g orally every 6 hours for 7-14 days. Or 500 mg intramuscularly every 12 hours.
50-100 mg/kg/day orally in 3-4 divided doses. Maximum 3 g/day.
None Documented
None Documented
Terminal elimination half-life is 9–12 hours in patients with normal renal function; may extend to >20 hours in impaired renal function, necessitating dose adjustment.
2-3 hours in normal renal function; prolonged to 24-30 hours in anuria or severe renal impairment; no significant change in hepatic disease.
Primarily renal excretion of unchanged drug via glomerular filtration; >90% of absorbed dose excreted unchanged in urine within 24 hours. Minor biliary excretion (<1%) with fecal elimination accounting for <1%.
Renal: >90% unchanged drug via glomerular filtration, with small amount reabsorbed; biliary/fecal: <2%.
Category C
Category C
Antibiotic
Antibiotic